Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-duration Ibrutinib + Obinutuzumab in Treatment-naïve CLL
NCT04908228Phase 2Recruiting
- Start
- Dec 2021
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab in chronic lymphocytic leukemia (CLL). Started Dec 2021; status: recruiting.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04908228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908228.